A5079345305- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Tracheal and airway disorders
- Mycobacterium research and diagnosis
- Reproductive Health and Technologies
- Respiratory Support and Mechanisms
- Hearing Loss and Rehabilitation
- Asthma and respiratory diseases
- Ear Surgery and Otitis Media
- Hearing, Cochlea, Tinnitus, Genetics
- Pulmonary Hypertension Research and Treatments
- Assisted Reproductive Technology and Twin Pregnancy
- Nematode management and characterization studies
- Bacteriophages and microbial interactions
- Microbial infections and disease research
University of Miami
2013-2025
University of Miami Hospital
2023
Jackson Memorial Hospital
2013
Abstract Background Nontuberculous Mycobacterium infections, particularly abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages available there great variation in phage susceptibilities M. abscessus isolates, requiring personalized identification. Methods isolates from 200...
Cystic fibrosis (CF) is caused by a mutation in the cystic transmembrane conductance regulator (CFTR) protein. Thousands of CFTR mutations have been identified, but only fraction are known to cause CF, with most common being prototypical class II F508del. Elexacaftor-Tezacaftor-Ivacaftor (ETI) modulator that significantly increases ppFEV1 and reduces exacerbation frequencies. It indicated for people CF (pwCF) 2 years or older at least one copy F508del other 177 responsive ETI based on...
Abstract Catamenial haemoptysis, the expectoration of blood during menses, has not been extensively reported in cystic fibrosis (CF) literature. We describe four cases (age range: 25–34 years) catamenial haemoptysis across CF centres United States. These may represent thoracic endometriosis versus hormonal fluctuations airway inflammation or infection resulting bronchial artery bleeding. identify common and nuanced management strategies including use pro‐coagulants, hormone contraceptives,...
As patients with cystic fibrosis live longer into their reproductive years, fertility concerns are rising. We hypothesized that while may be informed of the impact disease on potential, they remain unaware promising role assisted technology in helping them conceive biological children.We distributed a voluntary and anonymous survey to organizations assess patient understanding fibrosis-related infertility. The questions aimed capture demographic information, education regarding fibrosis,...
Cystic fibrosis (CF) is caused by a mutation in the cystic transmembrane conductance regulator (CFTR) protein. Thousands of CFTR mutations have been identified, but only fraction are known to cause CF, with most common being prototypical class II F508del. Elexacaftor-Tezacaftor-Ivacaftor (ETI), modulator that significantly increases ppFEV1 and reduces exacerbation frequencies indicated for people CF (pwCF) 6 years or older at least one copy F508del 170 responsive ETI based on clinical vitro...